Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Depreciation & Amortization (CF) (2016 - 2025)

Vistagen Therapeutics' Depreciation & Amortization (CF) history spans 14 years, with the latest figure at $54000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 38.46% year-over-year to $54000.0; the TTM value through Dec 2025 reached $187000.0, up 30.77%, while the annual FY2025 figure was $150000.0, 18.11% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $54000.0 at Vistagen Therapeutics, up from $53000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $54000.0 in Q4 2025 and bottomed at $31000.0 in Q4 2023.
  • The 4-year median for Depreciation & Amortization (CF) is $37000.0 (2024), against an average of $38807.7.
  • The largest annual shift saw Depreciation & Amortization (CF) skyrocketed 58.04% in 2021 before it rose 6.25% in 2024.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $36700.0 in 2021, then decreased by 15.53% to $31000.0 in 2023, then grew by 25.81% to $39000.0 in 2024, then skyrocketed by 38.46% to $54000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Depreciation & Amortization (CF) are $54000.0 (Q4 2025), $53000.0 (Q3 2025), and $40000.0 (Q2 2025).